List of Excipients in Branded Drug FETROJA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Shionogi Inc	FETROJA	cefiderocol sulfate tosylate	59630-266	NITROGEN	2029-11-14
Shionogi Inc	FETROJA	cefiderocol sulfate tosylate	59630-266	SODIUM CHLORIDE	2029-11-14
Shionogi Inc	FETROJA	cefiderocol sulfate tosylate	59630-266	SODIUM HYDROXIDE	2029-11-14
Shionogi Inc	FETROJA	cefiderocol sulfate tosylate	59630-266	SUCROSE	2029-11-14

FETROJA Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

FETROJA (cefiderocol) is a hospital-administered intravenous antibiotic whose commercial differentiation depends on activity against multidrug-resistant Gram-negative bacteria, not on a complex excipient system. The approved product is a sterile lyophilized powder in a single-dose vial. Its principal excipient opportunity is operational: improving reconstitution, reducing preparation errors, extending in-use stability, and enabling ready-to-use or closed-system hospital delivery while preserving cefiderocol stability and regulatory comparability.

What is FETROJA and how is it supplied?

FETROJA contains cefiderocol, a siderophore cephalosporin antibacterial. Shionogi developed and commercialized the product in the United States through Shionogi Inc. The FDA approved FETROJA on November 14, 2019, for specified infections caused by susceptible Gram-negative microorganisms, including complicated urinary tract infections and hospital-acquired or ventilator-associated bacterial pneumonia indications under the approved labeling framework.[1]

The marketed presentation is:

Attribute	FETROJA
Active ingredient	Cefiderocol
Dosage form	Sterile lyophilized powder for intravenous infusion
Strength	1 g cefiderocol per single-dose vial
Route	Intravenous infusion
Typical adult dosing	2 g every eight hours, adjusted for renal function
Reconstitution	Sterile Water for Injection
Further dilution	Compatible intravenous infusion solution, including sodium chloride 0.9% or dextrose 5% under labeled conditions
Manufacturer	Shionogi Inc.
FDA approval	November 14, 2019
Primary hospital use	Serious infections caused by resistant Gram-negative bacteria

FETROJA is used in acute-care hospitals and is generally administered by trained personnel. That setting creates a different commercial opportunity from outpatient oral drugs. Procurement decisions focus on microbiological coverage, stewardship, preparation time, pharmacy workflow, compatibility with automated compounding systems, and total treatment cost.

What excipients are used in FETROJA?

FETROJA has a relatively simple excipient profile compared with oral tablets, lipid formulations, depot injections, and biologics. The vial contains cefiderocol formulated as a sterile powder for reconstitution. The prescribing information identifies the formulation and handling requirements, while the final infusion uses a compatible diluent selected by the hospital pharmacy.[1]

Why the excipient burden is limited

The product does not need excipients for:

• Tablet compression
• Taste masking
• Gastrointestinal protection
• Modified release
• Transdermal permeation
• Suspension stabilization
• Long-term emulsion stability

The formulation instead must support:

1. Chemical stability during lyophilized storage.
2. Rapid dissolution after reconstitution.
3. Acceptable pH and osmolality for intravenous infusion.
4. Low particulate burden.
5. Compatibility with infusion bags, tubing and connectors.
6. Adequate stability during pharmacy preparation and administration.

The distinction between vial excipients and infusion diluents is commercially important. A hospital may use a diluent such as 0.9% sodium chloride or 5% dextrose even though that material is not necessarily part of the original drug product. Suppliers pursuing a FETROJA-compatible delivery product must therefore evaluate both the approved vial formulation and the final compounded infusion.

What excipient strategy is most suitable for cefiderocol?

The strongest strategy is a low-complexity parenteral formulation supported by process and delivery improvements rather than extensive new excipient loading.

Strategy 1: Optimize the lyophilized cake

A reformulation program could evaluate:

• Bulking agents to improve cake structure.
• Tonicity modifiers.
• Buffer systems.
• pH control.
• Collapse-temperature protection.
• Residual-moisture control.
• Reconstitution speed.
• Container-closure interaction.

The commercial value would come from a more robust manufacturing process and faster pharmacy preparation. A new formulation would need to demonstrate that the selected excipients do not alter cefiderocol degradation pathways, color, particulate formation, impurity profile, or antimicrobial potency.

Strategy 2: Develop a ready-to-use infusion

A ready-to-use presentation could eliminate or reduce:

• Vial reconstitution.
• Transfer steps.
• Needle or syringe handling.
• Pharmacy compounding time.
• Contamination risk.
• Dosing delays during urgent treatment.

Potential formats include:

• Premixed flexible infusion bags.
• Pharmacy bulk packages.
• Dual-chamber containers.
• Closed-system vial adapters.
• Ready-to-administer containers.
• Extended-use infusion devices.

For hospital buyers, preparation labor and medication-use safety can be as important as the cost of the active ingredient. The principal technical barrier is maintaining cefiderocol stability after dilution across the expected storage and administration period.

Strategy 3: Improve infusion-system compatibility

Cefiderocol delivery may be improved through validated compatibility with:

• Standard polyolefin infusion bags.
• Elastomeric pumps.
• Smart infusion pumps.
• Closed-system transfer devices.
• Automated compounding systems.
• Extended-infusion protocols.

This opportunity is less likely to require a new excipient than a new container-closure system and stability package. The intellectual-property position may be stronger if the innovation covers a specific combination of concentration, diluent, container material, storage condition and administration time.

Strategy 4: Reduce preparation variability

Hospitals may value a formulation with:

• A clearly visible reconstitution endpoint.
• Reduced foaming.
• Faster dissolution.
• Lower risk of vial overfill or underfill errors.
• Simplified renal-dose preparation.
• Labeling compatible with barcode medication administration.

These improvements can support a differentiated product even where the active molecule remains unchanged. The regulatory pathway would depend on whether the change affects composition, dosage form, container closure, stability, administration method or clinical performance.

What formulation patents could protect a FETROJA follow-on product?

Formulation-related protection may cover more than the named excipient. Potential claim categories include:

Claim category	Examples of protectable subject matter
Composition	Cefiderocol with a defined buffer, stabilizer, bulking agent or tonicity modifier
Lyophilized product	Defined residual moisture, cake structure, reconstitution time or impurity limits
Reconstituted solution	Cefiderocol concentration, pH, osmolality and degradation profile
Diluted infusion	Defined cefiderocol concentration in sodium chloride or dextrose
Container closure	Vial, bag, syringe, dual-chamber container or polymer system
Manufacturing process	Freeze-drying cycle, sterilization sequence or moisture-control process
Administration	Extended infusion, device-specific delivery or concentration-specific use
Stability	Storage period under refrigerated or room-temperature conditions
Combination	Cefiderocol with a specified infusion device or closed-system transfer method

A commercially meaningful patent should connect the excipient or device combination to a measurable performance benefit. Claims limited to routine substitution of one conventional excipient for another may face obviousness challenges, particularly if the substitution does not produce unexpected stability, safety or manufacturing results.

How strong is an excipient patent strategy for cefiderocol?

The strategy is strongest where the formulation solves a recognized hospital problem:

• Substantially longer post-reconstitution stability.
• Reduced degradation during extended infusion.
• Compatibility with a new delivery device.
• Lower particulate formation.
• Improved recovery from infusion containers.
• Reduced preparation time.
• Reliable use in automated compounding systems.

A weak strategy would rely on a broad claim to cefiderocol plus a conventional diluent without a demonstrated technical effect. The active ingredient’s existing regulatory and commercial history would also make later entrants vulnerable to patent-validity attacks if the formulation contribution is incremental.

When does FETROJA lose exclusivity?

FETROJA received FDA approval in 2019 and is protected by a combination of regulatory exclusivity, patent rights, formulation know-how and manufacturing controls. FDA approval alone does not establish a single generic-entry date. Entry depends on:

• Listed patents in the FDA Orange Book.
• The type of abbreviated application filed.
• Paragraph IV litigation.
• Pediatric exclusivity.
• Any settlement agreement.
• The scope of product, method-of-use and formulation claims.
• Approval timing for a competing applicant.

For a small-molecule injectable, an ANDA applicant may challenge listed patents through Paragraph IV certification. The applicant must show that the proposed product does not infringe, that the patent is invalid, or that the patent is unenforceable. A timely patent-infringement action can trigger a statutory stay of FDA approval for up to 30 months under the Hatch-Waxman framework.[2]

The relevant commercial conclusion is that active-ingredient expiry is not the only barrier. A generic cefiderocol product must also address injectable manufacturing, sterile processing, analytical comparability, container closure and any enforceable method-of-use or formulation patents.

What is the Orange Book status of FETROJA?

The FDA Orange Book is the controlling public source for determining whether FETROJA has listed patents and regulatory exclusivity relevant to ANDA applicants.[3] Orange Book listings can change through patent-expiration updates, delistings, corrections and new submissions.

For commercial diligence, the relevant review should cover:

• Patent numbers listed against FETROJA.
• Patent-use codes.
• Expiration dates.
• Pediatric extensions.
• Any patent-term adjustment.
• Whether a listed patent covers the drug substance, formulation, method of use or device.
• Whether the proposed generic can carve out the patented indication.

A method-of-use patent may not block approval for every use if an ANDA applicant submits a compliant section viii statement or otherwise excludes the patented indication from its labeling. A formulation patent covering the approved injectable product is more difficult to avoid if the proposed generic must use the same or a substantially similar formulation to obtain approval.

What Paragraph IV risks exist for FETROJA?

The principal Paragraph IV risks are likely to arise from an ANDA seeking approval for a cefiderocol injection rather than from biosimilar competition. Cefiderocol is a chemically synthesized small molecule, so the relevant pathway is generally ANDA approval, not the Biologics Price Competition and Innovation Act pathway.

Potential challenger arguments include:

• The asserted patent claims are invalid for obviousness.
• The claims lack written description or enablement.
• The proposed product does not practice the claimed formulation.
• The patent is not infringed because of a different excipient system.
• The patent is unenforceable because of inequitable conduct.
• The patented method of use can be carved out of the generic label.

Shionogi’s counterstrategy would likely focus on formulation equivalence, stability data, doctrine-of-equivalents theories, and the commercial importance of the claimed use. The strength of each dispute would depend on the actual Orange Book patents and the ANDA’s product composition.

Is biosimilar competition relevant to FETROJA?

No. FETROJA is a small-molecule antibiotic, not a biologic. Biosimilar approval under section 351(k) of the Public Health Service Act is therefore not the principal competitive pathway.[4]

The relevant competition consists of:

• Authorized generic or licensed generic supply.
• ANDA-approved cefiderocol injections.
• Other novel beta-lactam or beta-lactamase-inhibitor products.
• Polymyxins and aminoglycosides used as salvage therapy.
• Carbapenem-based therapies where susceptibility permits.
• Hospital antimicrobial stewardship protocols.

Which products compete with FETROJA?

FETROJA competes in the limited market for serious infections caused by resistant Gram-negative pathogens. Competitive products include newer beta-lactam and beta-lactamase-inhibitor combinations such as ceftazidime-avibactam, meropenem-vaborbactam and imipenem-cilastatin-relebactam. Cefiderocol’s commercial position depends on organism susceptibility, resistance mechanisms, infection site, renal function and institutional guidelines.

Product	Main commercial distinction	Excipient opportunity
FETROJA	Siderophore cephalosporin for resistant Gram-negative infections	Reconstitution, ready-to-use infusion, stability
Avycaz	Ceftazidime plus avibactam	Premix and infusion workflow
Vabomere	Meropenem plus vaborbactam	Stability and hospital administration
Recarbrio	Imipenem, cilastatin and relebactam	Container and infusion compatibility
Polymyxins	Older salvage therapies	Lower-cost alternatives, but toxicity concerns
Aminoglycosides	Susceptibility-dependent Gram-negative coverage	Dosing and monitoring workflow

FETROJA’s formulation opportunity is strongest where hospitals prioritize reliable preparation and rapid administration for critically ill patients. A product that reduces pharmacy workload without compromising stability could improve formulary adoption.

What commercial opportunities exist for FETROJA excipients?

Ready-to-use hospital products

A premixed cefiderocol infusion could capture value from hospital pharmacy labor and reduce manipulation. The commercial model could involve a branded reformulation, a contract-manufactured presentation, or a licensing arrangement with a specialist injectable manufacturer.

Excipient and packaging supply

Suppliers may pursue qualified materials for:

• Low-extractables infusion bags.
• Cefiderocol-compatible tubing.
• Sterile diluent containers.
• Dual-chamber systems.
• Vial adapters.
• Elastomeric pump reservoirs.
• Low-moisture vial closures.

The strongest candidates will have validated compatibility data and established regulatory files.

Contract development and manufacturing

CDMOs with sterile lyophilization, injectable filling and high-containment capabilities may offer:

• Cefiderocol formulation development.
• Scale-up and process validation.
• Aseptic filling.
• Lyophilization-cycle development.
• Stability testing.
• Container-closure qualification.
• ANDA support.

This market is narrower than the formulation market for high-volume chronic drugs, but the technical barriers are higher and hospital products can support premium pricing.

Hospital workflow products

An accessory product can create value without changing the drug formulation. Examples include:

• Validated reconstitution kits.
• Closed-system transfer assemblies.
• Barcode-enabled preparation systems.
• Infusion bags prefilled with approved diluent.
• Device-specific administration sets.

Such products may require separate regulatory analysis if marketed with a drug or as a combination product.

What manufacturing and IP barriers affect a FETROJA follow-on?

The principal barriers are sterile manufacturing and analytical control. A follow-on manufacturer must manage:

• Cefiderocol raw-material quality.
• Sterile filtration or aseptic processing.
• Lyophilization cycle reproducibility.
• Residual moisture.
• Degradation products.
• Visible and subvisible particles.
• Container-closure integrity.
• Reconstitution performance.
• Infusion-bag compatibility.
• Extractables and leachables.
• Microbiological quality.

The manufacturing process may be commercially important even where it is not publicly visible. A stable, high-yield lyophilization process can reduce cost and improve supply reliability. Process patents and trade secrets may therefore be more valuable than a broad excipient patent.

What licensing opportunities exist around FETROJA?

Potential licensing structures include:

1. A formulation license covering a stabilized cefiderocol composition.
2. A supply agreement for ready-to-use infusion bags.
3. A CDMO arrangement for sterile lyophilized vials.
4. A device license for closed-system reconstitution.
5. A regional commercialization license.
6. A hospital-contracting partnership focused on antimicrobial stewardship.

The most defensible transaction would combine formulation IP with manufacturing capability, regulatory data and a clear pathway to a differentiated presentation. A patent-only license without CMC data would have limited value because the principal risk is proving injectable stability and regulatory equivalence.

Key Takeaways

• FETROJA is a cefiderocol intravenous product supplied as a sterile lyophilized powder in a single-dose vial.
• Its excipient strategy is relatively simple and centers on stability, reconstitution and infusion compatibility.
• The highest-value opportunity is a ready-to-use or easier-to-prepare hospital presentation.
• Formulation patents are strongest when tied to measurable stability, compatibility or workflow benefits.
• FETROJA faces generic ANDA and Paragraph IV risk, not biosimilar risk.
• Orange Book patents, use codes and expiration dates determine the practical entry timeline.
• Sterile manufacturing, lyophilization and container-closure control are major barriers to follow-on entry.
• Licensing value is highest when formulation IP is paired with CMC data, manufacturing capacity and hospital distribution.

FAQs

Can cefiderocol be reformulated as an oral drug?

An oral reformulation would require a separate development program because cefiderocol is marketed for intravenous administration and serious resistant infections. Oral bioavailability, exposure at infection sites and clinical positioning would be major development issues.

Could a generic manufacturer use different excipients from FETROJA?

Yes, if the proposed formulation satisfies FDA requirements for pharmaceutical equivalence, product quality, stability, safety and efficacy and does not infringe enforceable patent claims.

Is a premixed FETROJA infusion likely to receive a 505(b)(2) approval?

A premixed product with a meaningful formulation or delivery change could potentially require a 505(b)(2) strategy, depending on the product’s composition, reliance on the reference product and requested labeling. The precise pathway would depend on FDA’s assessment.

What is the most valuable excipient for cefiderocol?

No single excipient is inherently the most valuable. The commercial value lies in a validated excipient system that improves stability, reconstitution or infusion compatibility without creating new safety or comparability problems.

Can a formulation patent delay generic cefiderocol entry?

Yes. An enforceable Orange Book-listed formulation patent can support a Paragraph IV litigation stay and delay FDA approval, subject to the patent’s scope, validity, enforceability and the challenger’s product design.

References

1. U.S. Food and Drug Administration. (2019). FETROJA (cefiderocol) prescribing information. Shionogi Inc.

2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biologic products. FDA.